Bayer loses another Nexavar compulsory licence appeal in India

16-07-2014

Bayer loses another Nexavar compulsory licence appeal in India

360b / Shutterstock.com

The Mumbai High Court has upheld India-based Natco Pharma’s compulsory licence on Bayer’s kidney cancer drug Nexavar (sorafenib).


Bayer, Nexavar, Natco Pharma, compulsory licence, Mumbai High Court

LSIPR